Cargando…
Moving beyond first-line treatment options for OCD
OCD is characterized by obsessions and compulsions that cause distress, are time-consuming, and interfere with a patient's social, occupational, or other areas of functioning. SSRIs are first-line pharmacologic treatment options and produce response rates of up to 60% in patients with OCD. Seve...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association of Psychiatric Pharmacists
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645290/ https://www.ncbi.nlm.nih.gov/pubmed/36405507 http://dx.doi.org/10.9740/mhc.2022.10.300 |
_version_ | 1784826934465658880 |
---|---|
author | Paxos, Chris |
author_facet | Paxos, Chris |
author_sort | Paxos, Chris |
collection | PubMed |
description | OCD is characterized by obsessions and compulsions that cause distress, are time-consuming, and interfere with a patient's social, occupational, or other areas of functioning. SSRIs are first-line pharmacologic treatment options and produce response rates of up to 60% in patients with OCD. Several potential strategies have been evaluated for enhancing patient response, including high-dose SSRI therapy, antipsychotic augmentation, and memantine augmentation. Three patient cases are used to explore treatment guidelines, evaluate existing literature, and provide pharmacotherapy recommendations for the management of patients with OCD when first-line therapy fails. |
format | Online Article Text |
id | pubmed-9645290 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association of Psychiatric Pharmacists |
record_format | MEDLINE/PubMed |
spelling | pubmed-96452902022-11-18 Moving beyond first-line treatment options for OCD Paxos, Chris Ment Health Clin Psychopharmacology Pearls OCD is characterized by obsessions and compulsions that cause distress, are time-consuming, and interfere with a patient's social, occupational, or other areas of functioning. SSRIs are first-line pharmacologic treatment options and produce response rates of up to 60% in patients with OCD. Several potential strategies have been evaluated for enhancing patient response, including high-dose SSRI therapy, antipsychotic augmentation, and memantine augmentation. Three patient cases are used to explore treatment guidelines, evaluate existing literature, and provide pharmacotherapy recommendations for the management of patients with OCD when first-line therapy fails. American Association of Psychiatric Pharmacists 2022-11-03 /pmc/articles/PMC9645290/ /pubmed/36405507 http://dx.doi.org/10.9740/mhc.2022.10.300 Text en © 2022 AAPP. The Mental Health Clinician is a publication of the American Association of Psychiatric Pharmacists. https://creativecommons.org/licenses/by-nc/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Psychopharmacology Pearls Paxos, Chris Moving beyond first-line treatment options for OCD |
title | Moving beyond first-line treatment options for OCD |
title_full | Moving beyond first-line treatment options for OCD |
title_fullStr | Moving beyond first-line treatment options for OCD |
title_full_unstemmed | Moving beyond first-line treatment options for OCD |
title_short | Moving beyond first-line treatment options for OCD |
title_sort | moving beyond first-line treatment options for ocd |
topic | Psychopharmacology Pearls |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645290/ https://www.ncbi.nlm.nih.gov/pubmed/36405507 http://dx.doi.org/10.9740/mhc.2022.10.300 |
work_keys_str_mv | AT paxoschris movingbeyondfirstlinetreatmentoptionsforocd |